Chief Executive Officer and Executive Board Member
Olivier Morand is a senior leader in pharma strategic development for early- and late-phase products with many years of hand-on experience in orphan drug development. He brings a broad scientific and clinical development know-how as well as a business insight and leadership acumen to the Azafaros team. He has a very strong industry track record, most recently as Senior Director, Clinical Science Early and Special Projects, at Idorsia Pharmaceuticals. Previously, he worked as Senior Director, Global Life Cycle Leader, at Actelion Pharmaceuticals and as Scientific Expert and Project Leader in the Department of Drug Discovery for Metabolic and Vascular Diseases at F. Hoffmann-La Roche. While at Actelion and Idorsia, he played a decisive role in the submission and approval of miglustat for Niemann-Pick type C in the European Union and Japan, and in the conception and execution of the development strategy for lucerastat in Fabry disease.
In his early career, Olivier held various roles in academic institutions such as the Laboratory of Neurochemistry U134 at INSERM in Paris, the Department of Biochemistry at Hadassah Medical School in Jerusalem, the Department of Human Genetics at Mount Sinai School of Medicine in New York, NY, and the Department of Biochemistry at the University of Wisconsin, Madison WI.
Olivier holds a PhD in Nutrition and a PhD in Biology and Genetics from the University Paris and is an IMD (Lausanne) alumnus (Program for Executive Development).